Shots:

• The positive opinion is based on P-I/II HGB-205 & Northstar (HGB-204) and P-III Northstar-2 (HGB-207) & Northstar-3 (HGB-212) studies assessing Zynteglo in patients with transfusion-dependent β-thalassemia (TDT) who do not have β0/β0 genotype aged 12 yrs. and older
• Collective data from studies: 80% achieved transfusion independence with median duration of 38 mos.; @6mos. median (min – max) total hemoglobin for patients was 11.9 g/dL
• Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) is a gene therapy- formerly known as LentiGlobin targeted for TDT and reviewed under EMA’s PRIME and Adaptive Pathways programs with its expected European Commission approval in Q2’19

  Ref: Bluebird Bio | Image: Twitter